MX2019008921A - Adenovirus recombinante de transgenes múltiples. - Google Patents
Adenovirus recombinante de transgenes múltiples.Info
- Publication number
- MX2019008921A MX2019008921A MX2019008921A MX2019008921A MX2019008921A MX 2019008921 A MX2019008921 A MX 2019008921A MX 2019008921 A MX2019008921 A MX 2019008921A MX 2019008921 A MX2019008921 A MX 2019008921A MX 2019008921 A MX2019008921 A MX 2019008921A
- Authority
- MX
- Mexico
- Prior art keywords
- recombinant adenovirus
- multiple transgene
- transgene recombinant
- insertion site
- transgenes
- Prior art date
Links
- 108700019146 Transgenes Proteins 0.000 title abstract 3
- 241000701161 unidentified adenovirus Species 0.000 title abstract 2
- 230000037431 insertion Effects 0.000 abstract 2
- 238000003780 insertion Methods 0.000 abstract 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 abstract 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 abstract 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 abstract 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 abstract 1
- -1 e.g. Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762452342P | 2017-01-30 | 2017-01-30 | |
| US201762520945P | 2017-06-16 | 2017-06-16 | |
| PCT/US2018/016032 WO2018140973A1 (en) | 2017-01-30 | 2018-01-30 | Multiple transgene recombinant adenovirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019008921A true MX2019008921A (es) | 2019-11-08 |
Family
ID=62978741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008921A MX2019008921A (es) | 2017-01-30 | 2018-01-30 | Adenovirus recombinante de transgenes múltiples. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190352616A1 (https=) |
| EP (1) | EP3574090A4 (https=) |
| JP (1) | JP2020505049A (https=) |
| KR (1) | KR20190128634A (https=) |
| CN (1) | CN110741080A (https=) |
| AU (1) | AU2018213417A1 (https=) |
| BR (1) | BR112019015600A2 (https=) |
| CA (1) | CA3052090A1 (https=) |
| IL (1) | IL268291A (https=) |
| MX (1) | MX2019008921A (https=) |
| SG (1) | SG11201906973TA (https=) |
| WO (1) | WO2018140973A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| KR102608590B1 (ko) | 2014-09-24 | 2023-12-01 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양 살상 바이러스 및 이의 사용방법 |
| WO2017147269A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES |
| EA201990822A1 (ru) | 2017-04-12 | 2020-01-09 | Эписентарикс, Инк. | Иммуномодулирующие слитые белки |
| US20200155625A1 (en) * | 2017-05-24 | 2020-05-21 | Epicentrx, Inc. | Anti-angiogenic adenovirus |
| CN112292449A (zh) | 2018-04-09 | 2021-01-29 | 萨克生物研究学院 | 具有增强的复制特性的溶瘤腺病毒组合物 |
| WO2022007800A1 (zh) * | 2020-07-06 | 2022-01-13 | 嘉兴安宇生物科技有限公司 | 一种非洲猪瘟的重组腺病毒疫苗及其构建方法 |
| EP4349975A4 (en) * | 2021-05-25 | 2025-04-16 | Voncolytic Therapeutics Co., Ltd. | Chimeric broad-spectrum oncolytic adenovirus with multiple mechanisms synergizing with and enhancing efficacy of immunotherapy, and application thereof in tumor treatment |
| CN113249342B (zh) * | 2021-05-25 | 2023-12-01 | 江苏万戎生物医药科技有限公司 | 一款多重机制协同和增效免疫治疗的嵌合型广谱溶瘤腺病毒及其在肿瘤治疗中的应用 |
| WO2024015876A1 (en) | 2022-07-13 | 2024-01-18 | Epicentrx, Inc. | Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100896483B1 (ko) * | 2007-07-13 | 2009-05-08 | 연세대학교 산학협력단 | Ｉｌ-12 및 4-1ｂｂｌ을 발현하는 종양 선택적 살상 재조합아데노바이러스 및 수지상 세포를 유효성분으로 포함하는항종양용 약제학적 조성물 |
| HUE026386T2 (en) * | 2009-03-02 | 2016-06-28 | Univ California | Tumor-selective adenovirus e1a and e1b mutants |
| KR20130010121A (ko) * | 2010-03-23 | 2013-01-25 | 인트렉손 코포레이션 | 치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도 |
| US20130243731A1 (en) * | 2010-09-24 | 2013-09-19 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti-ctla-4 antibodies |
| WO2013116778A2 (en) * | 2012-02-02 | 2013-08-08 | Board Of Regents | Immunogenic adenovirus |
| DK2986311T3 (en) * | 2013-04-18 | 2019-02-25 | Tilt Biotherapeutics Oy | IMPROVED ADOPTIVE CELL THERAPY |
| CN103614416B (zh) * | 2013-09-30 | 2016-09-07 | 中国人民解放军第二军医大学东方肝胆外科医院 | 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途 |
| KR102608590B1 (ko) * | 2014-09-24 | 2023-12-01 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양 살상 바이러스 및 이의 사용방법 |
| US10232053B2 (en) * | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
-
2018
- 2018-01-30 CA CA3052090A patent/CA3052090A1/en active Pending
- 2018-01-30 EP EP18743942.7A patent/EP3574090A4/en not_active Withdrawn
- 2018-01-30 KR KR1020197025498A patent/KR20190128634A/ko not_active Ceased
- 2018-01-30 WO PCT/US2018/016032 patent/WO2018140973A1/en not_active Ceased
- 2018-01-30 AU AU2018213417A patent/AU2018213417A1/en not_active Abandoned
- 2018-01-30 CN CN201880021787.6A patent/CN110741080A/zh active Pending
- 2018-01-30 JP JP2019541188A patent/JP2020505049A/ja active Pending
- 2018-01-30 MX MX2019008921A patent/MX2019008921A/es unknown
- 2018-01-30 US US16/482,055 patent/US20190352616A1/en not_active Abandoned
- 2018-01-30 SG SG11201906973TA patent/SG11201906973TA/en unknown
- 2018-01-30 BR BR112019015600-3A patent/BR112019015600A2/pt not_active Application Discontinuation
-
2019
- 2019-07-28 IL IL268291A patent/IL268291A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201906973TA (en) | 2019-08-27 |
| EP3574090A1 (en) | 2019-12-04 |
| JP2020505049A (ja) | 2020-02-20 |
| KR20190128634A (ko) | 2019-11-18 |
| BR112019015600A2 (pt) | 2020-03-17 |
| EP3574090A4 (en) | 2021-01-06 |
| WO2018140973A1 (en) | 2018-08-02 |
| IL268291A (en) | 2019-09-26 |
| CN110741080A (zh) | 2020-01-31 |
| CA3052090A1 (en) | 2018-08-02 |
| AU2018213417A1 (en) | 2019-08-15 |
| US20190352616A1 (en) | 2019-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019008921A (es) | Adenovirus recombinante de transgenes múltiples. | |
| ZA201908445B (en) | Recombinant adenoviruses carrying transgenes | |
| SG11202111149VA (en) | Plasmid system | |
| MX2025014378A (es) | Composiciones utiles para la edicion del gen ttr y el tratamiento de la amiloidosis attr | |
| SG11202103314QA (en) | Engineered genetic modulators | |
| IL284742A (en) | AAV-mediated gene therapy restoring the autoperlin gene | |
| EP4555965A3 (en) | Robotic surgical devices, systems and related methods | |
| SG11201912179SA (en) | Targeted non-viral dna insertions | |
| MY185390A (en) | Antisense nucleic acids | |
| PL3722434T3 (pl) | Układ plazmidowy | |
| SG11202000650YA (en) | Factor viii (fviii) gene therapy methods | |
| GB201805567D0 (en) | Implant alignment system | |
| MX2019006552A (es) | Terapia génica para mucopolisacaridosis de tipo i. | |
| SG11202010676TA (en) | Improved t-cell therapy | |
| IL279685A (en) | Gene therapy | |
| GB201905301D0 (en) | Gene therapy | |
| MX2018000984A (es) | Terapias de combinacion. | |
| GB201819426D0 (en) | Implant assembly and associated methods | |
| GB201802326D0 (en) | Gene therapy | |
| SG11202006740QA (en) | Gaming system | |
| GB201817470D0 (en) | Gene therapy | |
| EP3548036A4 (en) | NATURAL COMBINATION HORMONE REPLACEMENT FORMULAS AND THERAPIES | |
| ZA202007857B (en) | Gaming system | |
| EA201991805A1 (ru) | Множественно трансгенный рекомбинантный аденовирус | |
| Disney | Mahasi Sasana Yeiktha (six sijo/stlings) |